Get the Stockscreener App
66.65
1.41%
-0.95
After Hours:
66.10
-0.55
-0.83%
Bright Minds Biosciences Inc stock is traded at $66.65, with a volume of 300.41K.
It is down -1.41% in the last 24 hours and down -3.41% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$67.60
Open:
$67.83
24h Volume:
300.41K
Relative Volume:
1.04
Market Cap:
$653.97M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-27.29
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-3.66%
1M Performance:
-3.41%
6M Performance:
-28.49%
1Y Performance:
+134.93%
1-Day Range:
$65.18
$69.42
1-Week Range:
$65.18
$73.58
52-Week Range:
$24.00
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
66.65 | 688.81M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Best TSX Healthcare Stocks to Watch for July 2026 - Kalkine Media
Avoiding Lag: Real-Time Signals in (DRUG) Movement - Stock Traders Daily
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
BrightSpring Health Services, Inc. (BTSG) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences Inc (DRUG) Stock Forum and Discussion - Moomoo
DRUG Forecast — Price Target — Prediction for 2027 - TradingView
Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG) - TradingView
Bright Minds Biosciences Inc. (DRUG) Shows Modest Uptick, Testing Key ResistanceGap Fill Strategy - dars.gov.et
$ENA Forecast — Price Prediction for 2026. Should I Buy $ENA? - Intellectia AI
DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Income Statement - Intellectia AI
DRUG Technical Analysis & Stock Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in DRUG Response - Stock Traders Daily
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bright Minds Biosciences Inc - TradingKey
Bright Minds Biosciences Inc (DRUG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bright Minds Biosciences (DRUG) Slides 1% as Buyers and Sellers Battle Near Critical LevelsBull Flag - newsline.com
Behavioral Patterns of DRUG and Institutional Flows - Stock Traders Daily
Bright Minds Biosciences (DRUG) Surges 3.86% as Shares Test Key Resistance ZoneMomentum Trade - newsline.com
News Releases for Bright Minds Biosciences Inc. - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences Dips 4.28% as Biotech Volatility ResurfacesOpening Range Breakout - newsline.com
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) details 2026 AGM, board nominees and auditor - Stock Titan
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data - Investing.com UK
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting - TipRanks
Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates - Stock Titan
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145 - Moomoo
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com - Investing.com South Africa
DRUG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $145 - GuruFocus
(DRUG) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options - The Globe and Mail
Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk - Stock Titan
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference - Weekly Voice
Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event - Stock Titan
Bright Minds Biosciences (DRUG) Edges Higher Amid Consolidation Near Key Support LevelLiquidity Order Flow - newsline.com
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - AOL.com
B Group Discloses New Position in Bright Minds Biosciences - HarianBasis.co
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool
Bright Minds Biosciences Stock Jumps After $220 Piper Sandler Call—What DRUG Traders Are Watching - Bez Kabli
Piper Sandler raises Bright Minds stock price target on program progress - Investing.com UK
Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220 - Moomoo
Piper Sandler raises Bright Minds stock price target on program progress By Investing.com - Investing.com South Africa
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing - TipRanks
[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC FilingForm 6-K - Stock Titan
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):